Oncology Biosimilars Market

Global Oncology Biosimilars Market Overview:

Cancer is attributed as the second leading cause of fatalities across the world. According to the World Health Organization, an estimated 9.6 million deaths occurred in 2018. Naturally, pharmaceutical companies have boosted cancer treatment drugs production to cater to such a large pool of patients.

Since blockbuster biologic drugs are quite expensive, the stage is set for the entry of biosimilar and generic drugs. Based on these trends, the oncology biosimilars market is looking at a bright future ahead expanding at a stellar CAGR of 29.4% by 2025 end.

The ongoing COVID-19 pandemic, however, is anticipated to inhibit progress in the short-run. Supply shortages, owing to nationwide lockdowns across emerging economies, are anticipated to occur. Likewise, the shifted focus of healthcare providers to care for COVID-19 patients are poised to delay evaluation and uptake of biosimilar drugs.

This is because healthcare providers would prefer to stick to the status quo therapy options and proceed with existing drugs. Moreover, delays in biosimilar clinical trials are further anticipated to limit growth prospects in the near-term. However, post-COVID-19, the global oncology biosimilars market shall experience a resurgence.

Global Oncology Biosimilars Market Analysis by Disease Indication:

The blood cancers segment is projected to expand the fastest, at a whopping 33.0% CAGR during the forecast period. This is mostly attributed to a rising number of novel drugs in the pipeline of key manufacturers. The blood cancers segment is anticipated to capture more than 1/5th of the total oncology biosimilars market.

However, the neutropenia segment is poised to dominate the global oncological biosimilars market, capturing more than half of the total market share. Expiration of patented blockbuster biologics has paved way for increased usage of biosimilar products in the segment.

In 2018, the FDA approved the use of filgrastim-aafi manufactured by Pfizer, for treating neutropenia among patients who have undergone blood cancer treatment. The neutropenia segment is anticipated to expand at a dexterous CAGR of 29.6%.

Global Oncology Biosimilars Market Regional Insights:

The Asia-Pacific oncology biosimilars market is set to register aggrandizing growth, expanding at a CAGR of 30.7%, thus reaching a position of market dominance. The Asia-Pacific market is poised to capture more than one-third of the overall market. This impressive growth trajectory is attributed to active collaboration within market giants to expand profit pools. For instance, in 2016, Dr. Reddy’s Laboratories collaborated with TR-Pharm to commercialize the former’s three biosimilars in Turkey.

North America presents equally lucrative growth opportunities. Burgeoning investment in research and development to develop pipeline portfolios is a key growth driver of the region. Biocon, a leading Indian pharmaceutical company, owns three pipeline biosimilars in the oncology segment.

Apotex Inc. has five biosimilars in its pipeline. Together, the companies have introduced these drugs into the market. The North American oncology biosimilars market is set to expand at a CAGR of 32.0%, capturing over a quarter of the market.

Global Oncology Biosimilars Market Companies’ Strategies

The global oncology biosimilars market consists of the following market players: Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBh. This makes it a highly consolidated market. Collectively, these market players account for more than 70% of the market share. In order to broad based their market footprints, these companies rely heavily on strengthening their product distribution networks through active collaborations.

Biocon, for instance, announced an exclusive global collaboration with Sandoz on next-generation biosimilars in 2018. Likewise, Dr. Reddy’s collaborated with TR Pharm to launch three biosimilars in Turkey in 2016. Other prominent market players in the global oncology biosimilars market include Pfizer, Inc., Celltrion, Inc., Sandoz International GmBh, STADA Arzneimittel AG and Apotex, Inc. to name a few.

COVID-19’s Impact on Oncology Biosimilars Market:

The ongoing COVID-19 pandemic has brought the world to a standstill. With business operations getting suspended, industries are facing supply chain disruptions and a subsequent demand-supply gap. With regard to oncology biosimilars, the market is anticipated to register a decline in the short-run. This is attributed to shifting priorities of healthcare providers towards addressing patients with acute COVID-19 infections.

Delays in clinical trials are anticipated, owing to this, which will eventually delay product launches. Fortunately, providers are looking for options to compensate for the extra expenses they are incurring at the present moment. It will become more important than ever for biosimilars to deliver on their promise of bringing savings to the healthcare system.

Analyst’s Viewpoint:

The global oncology biosimilars market is set to embark on a positive growth path throughout the forecast period. Blockbuster generic drugs have now reached a cliffhanger, anticipated to soon phase out. This is providing immense opportunities for companies operating in this market to expand their product portfolios. Moreover, lucrative opportunities exist in the Asia-Pacific, owing to presence of important market players as well as increasing cancer cases attributed to sedentary lifestyles.

Global Oncology Biosimilars Market: Report Scope:

The recent study on oncology biosimilars published by Fact.MR incorporates a 5-year forecast period from 2020 to 2025 and explicates on vital dynamics such as the key drivers, opportunities and restraints for the market. The report analyses the market based on the following segments: drug class, disease indication and distribution channel. Each segment includes a detailed analysis in terms of market share, revenue and overall growth.

A section on regional analysis has been included based on the following four geographies: North America, Europe, Asia-Pacific and Rest of the World. Each region has been analyzed based on the aforementioned segments.

Global Oncology biosimilars Market Segmentation

Fact.MR has studied the global oncology biosimilars market with detailed segmentation on the basis of drug class, disease indication, distribution channel, and region.

Drug Class

• G-CSF
• Monoclonal Antibody
• Hematopoietic Agents

Disease Indication

• Breast Cancer
• Non-Small Cell Lung Cancer
• Colorectal Cancer
• Neutropenia
• Blood Cancer:
• Leukemia:
• Myeloid Leukemia
• Chronic Lymphocytic Leukemia (CLL)
• Non-Hodgkin Lymphoma
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Region

• North America
• Europe
• Asia Pacific
• Rest of the World

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than the addressee(s) is unauthorized and prohibited.”

Global Oncology Biosimilars Market- Scope Of The Report

The recent study by Fact.MR on the global oncology biosimilars market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends currently determining the growth of the market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the production of oncology biosimilars products. The study also provides dynamics responsible for influencing the future status of the global oncology biosimilars market over the forecast period.

A detailed assessment of the global oncology biosimilars market’s value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global oncology biosimilars market along with their product portfolio enhances the reliability of this comprehensive research study.

Global Oncology Biosimilars Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the global oncology biosimilars market across the globe.

A comprehensive estimate on the global oncology biosimilars market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of global oncology biosimilars market during the forecast period.

Global Oncology Biosimilars Market: Analysis on Market Size Evaluation

The global oncology biosimilars market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for global oncology biosimilars market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent global oncology biosimilars market segments, along with market attractiveness evaluation has been incorporated in the report.

Global Oncology Biosimilars Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global oncology biosimilars report, which have helped deliver projections on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the global oncology biosimilars market during the forecast period.

Country-specific valuation on demand for global oncology biosimilars has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value for emerging countries has also been included in the report.

Global Oncology Biosimilars Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading manufacturers of global oncology biosimilars products along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of global oncology biosimilars products, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.